Artículos por temáticas

In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment.

Bagga P, Chugani AN, Varadarajan KS, Patel AB.

J Neurochem. 2013 Nov;127(3):365-77. doi: 10.1111/jnc.12407.

Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale.

Antonini A, Abbruzzese G, Ferini-Strambi L, Tilley B, Huang J, Stebbins GT, Goetz CG, Barone P; MDS-UPDRS Italian Validation Study Group., Bandettini di Poggio M, Fabbrini G, Di Stasio F, Tinazzi M, B

Neurol Sci. 2013 May;34(5):683-7. doi: 10.1007/s10072-012-1112-z.

Tnfaip8l1/Oxi-β binds to FBXW5, increasing autophagy through activation of TSC2 in a Parkinson's disease model.

Ha JY, Kim JS, Kang YH, Bok E, Kim YS, Son JH.

J Neurochem. 2013 Dec 26. doi: 10.1111/j.1471-4159.2013.12643.x. [Epub ahead of print]

Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.

Scherfler C, Esterhammer R, Nocker M, Mahlknecht P, Stockner H, Warwitz B, Spielberger S, Pinter B, Donnemiller E, Decristoforo C, Virgolini I, Schocke M, Poewe W, Seppi K.

Brain. 2013 Oct;136(Pt 10):3028-37. doi: 10.1093/brain/awt234.

Trial designs used to study neuroprotective therapy in Parkinson's disease.

Lang AE, Melamed E, Poewe W, Rascol O.

Mov Disord. 2013 Jan;28(1):86-95. doi: 10.1002/mds.24997. Review.

TARDBP mutations in Parkinson's disease.

Rayaprolu S, Fujioka S, Traynor S, Soto-Ortolaza AI, Petrucelli L, Dickson DW, Rademakers R, Boylan KB, Graff-Radford NR, Uitti RJ, Wszolek ZK, Ross OA.

Parkinsonism Relat Disord. 2013 Mar;19(3):312-5. doi: 10.1016/j.parkreldis.2012.11.003.

Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.

Chen W, Wang H, Wei H, Gu S, Wei H.

J Neurol Sci. 2013 Jan 15;324(1-2):21-8. doi: 10.1016/j.jns.2012.08.030. Review.

α-Synuclein and mitochondrial dysfunction in Parkinson's disease.

Mullin S, Schapira A.

Mol Neurobiol. 2013 Apr;47(2):587-97. doi: 10.1007/s12035-013-8394-x. Review.

Reduced body mass index in Parkinson's disease: contribution of comorbid depression.

Pilhatsch M, Kroemer NB, Schneider C, Ebersbach G, Jost WH, Fuchs G, Odin P, Reifschneider G, Bauer M, Reichmann H, Storch A.

J Nerv Ment Dis. 2013 Jan;201(1):76-9. doi: 10.1097/NMD.0b013e31827ab2cc.

Screening for anxiety symptoms in Parkinson disease: a cross-sectional study.

Stefanova E, Ziropadja L, Petrović M, Stojković T, Kostić V.

J Geriatr Psychiatry Neurol. 2013 Mar;26(1):34-40. doi: 10.1177/0891988713476368.

Supplementary motor area stimulation for Parkinson disease: a randomized controlled study.

Shirota Y, Ohtsu H, Hamada M, Enomoto H, Ugawa Y; Research Committee on rTMS Treatment of Parkinson's Disease..

Neurology. 2013 Apr 9;80(15):1400-5. doi: 10.1212/WNL.0b013e31828c2f66.

Anaesthetic Management of a Geriatric Patient with Parkinson's Disease, who was Posted for Emergency Laparotomy- A Case Report.

Holyachi RT, Karajagi S, Biradar SM.

J Clin Diagn Res. 2013 Jan;7(1):148-9. doi: 10.7860/JCDR/2012/5175.2691.

[Molecular markers of endothelial damage in patients with Parkinson's disease].

Makarov NS, Spiridonova SV, Nikitina VV, Voskresenskaia ON, Zakharova NB.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(3):61-4. Russian.

Neurosteroid and neurotransmitter alterations in Parkinson's disease.

di Michele F, Luchetti S, Bernardi G, Romeo E, Longone P.

Front Neuroendocrinol. 2013 Apr;34(2):132-42. doi: 10.1016/j.yfrne.2013.03.001. Review.

The risk of venous thromboembolism in older patients with advanced stages of Parkinson's disease.

Lauretani F, Maggio M, Giordano A, Ceda GP, Nardelli A.

Aging Clin Exp Res. 2013 May;25(2):229-30. doi: 10.1007/s40520-013-0022-0. No abstract available.